Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2013 - 2026)

Sarepta Therapeutics' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $136.4 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 58.04% year-over-year to $136.4 million; the TTM figure through Mar 2026 stood at $136.4 million (down 58.04% YoY), while the FY2025 annual figure was $83.9 million, down 74.18% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $136.4 million, up from $83.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $552.2 million in Q1 2022, with the low at $83.9 million in Q4 2025.
• The 5-year median for Non-Current Deffered Revenue is $437.0 million (2023), against an average of $387.5 million.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2025, while the deepest fall reached 74.18% in 2025.
• Sarepta Therapeutics' Non-Current Deffered Revenue stood at $485.0 million in 2022, then declined by 9.9% to $437.0 million in 2023, then slipped by 25.63% to $325.0 million in 2024, then slumped by 74.18% to $83.9 million in 2025, then surged by 62.5% to $136.4 million in 2026.
• Business Quant data shows SRPT's Non-Current Deffered Revenue at $136.4 million in Q1 2026, $83.9 million in Q4 2025, and $325.0 million in Q1 2025.